Patents by Inventor James J. Crute

James J. Crute has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and labeled molecules for determining ligand binding to steroid receptors
    Publication number: 20030017503
    Abstract: The invention relates to fluorescence polarization (FP) methods for detecting and evaluating ligand binding to steroid receptors which are associated with heat shock proteins (hsps). The invention also relates to novel labeled molecules, in particular, fluorescence probes, which are useful in the methods of the invention.
    Type: Application
    Filed: May 20, 2002
    Publication date: January 23, 2003
    Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Susan E. Goldrick, Richard M. Nelson, James J. Crute, Ruby C. Wasti, Gerald H. Nabozny, John R. Proudfoot, David S. Thomson
  • Anti-herpesvirus compounds and methods for identifying, making and using same
    Patent number: 6458959
    Abstract: This invention relates to methods for inhibiting herpes replication and for treating herpes infection in a mammal by inhibiting the herpes helicase-primase enzyme complex. This invention also relates to thiazolyphenyl derivatives that inhibit the herpes helicase-primase and to pharmaceutical compositions comprising the thiazolylphenyl derivatives, to methods of using and methods of producing the thiazolylphenyl derivatives.
    Type: Grant
    Filed: October 10, 2000
    Date of Patent: October 1, 2002
    Assignees: Boehringer Ingelheim Pharmaceuticals, Inc., Boehringer Ingelheim (Canada) Ltd.
    Inventors: James J. Crute, Anne-Marie Faucher, Christine A. Grygon, Karl D. Hargrave, Bruno Simoneau, Bounkham Thavonekham
  • Anti-herpesvirus compounds and methods for identifying, making and using same
    Patent number: 6348477
    Abstract: This invention relates to methods for inhibiting herpes replication and for treating herpes infection in a mammal by inhibiting the herpes helicase-primase enzyme complex. This invention also relates to thiazolyphenyl derivatives that inhibit the herpes helicase-primase and to pharmaceutical compositions comprising the thiazolylphenyl derivatives, to methods of using and methods of producing the thiazolylphenyl derivatives.
    Type: Grant
    Filed: December 8, 1999
    Date of Patent: February 19, 2002
    Assignees: Boehringer Ingelheim(Canada) Ltd., Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: James J. Crute, Anne-Marie Faucher, Christine A. Grygon, Karl D. Hargrave, Bruno Simoneau, Bounkham Thavonekham
  • High throughput compatible assay for receptor-TRAF interactions
    Patent number: 6143507
    Abstract: Disclosed is a high throughput compatible assay that is useful for the identification of specific antagonists of TRAF-receptor interactions. The modular flexibility of the assay makes it possible to introduce simple modifications in order to measure the interaction of any TNF receptor cytoplasmic domain (or TRAF-binding protein) with any of the six TRAF proteins, TRAF1, TRAF2, TRAF3, TRAF4, TRAF5 and TRAF6.
    Type: Grant
    Filed: October 29, 1998
    Date of Patent: November 7, 2000
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Marilyn R. Kehry, Steven S. Pullen, James J. Crute
  • Anti-herpesvirus compounds and methods for identifying, making and using same
    Patent number: 6057451
    Abstract: This invention relates to methods for inhibiting herpes replication and for treating herpes infection in a mammal by inhibiting the herpes helicase-primase enzyme complex. This invention also relates to thiazolyphenyl derivatives that inhibit the herpes helicase-primase and to pharmaceutical compositions comprising the thiazolylphenyl derivatives, to methods of using and methods of producing the thiazolylphenyl derivatives.
    Type: Grant
    Filed: December 4, 1996
    Date of Patent: May 2, 2000
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: James J. Crute, Anne-Marie Faucher, Christine A. Grygon, Karl D. Hargrave, Bruno Simoneau, Bounkham Thavonekham
  • Quantitative solid phase helicase assay
    Patent number: 5958696
    Abstract: This invention relates to a solid phase helicase assay for identifying helicase inhibitors. The assay having a model helicase substrate adsorbed on a solid support, the model helicase substrate being an immobilized extended single-stranded nucleic acid polymer hybridized to a labeled helicase reaction product. The presence of the labeled helicase reaction product is detectable in solution on helicase activity. Also described is a method for measuring the helicase inhibiting ability of test substances thus, making the assay useful for identifying pharmaceutically important helicase inhibitors.
    Type: Grant
    Filed: May 22, 1998
    Date of Patent: September 28, 1999
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventor: James J. Crute